公开(公告)号：EP1886692A1

公开(公告)日：2008-02-13

申请号：EP06746919.7

申请日：2006-05-26

申请人： Asubio Pharma Co., Ltd.

发明人： WAKABAYASHI, Naomi BioPharma Center, ASUBIO PHARMA CO., ltd. ,  HARADA, Yuriko ,  MASUDA, Yutaka BioPharma Center, ASUBIO PHARMA CO., ltd.

IPC分类号： A61K45/00 ,  A61K38/04 ,  A61K38/22 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12

CPC分类号： A61K9/0043 ,  A61K9/0019 ,  A61K9/0073 ,  A61K38/26

摘要： A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also provided is an insulin resistance improver for use in the dosage regimen. The dosage regimen comprises repeatedly administering, preferably in a non-invasive manner, a GLP-1 receptor agonist at least before eating for a predetermined period of time to create a condition similar to what is observed with postprandial temporary secretion of the endogenous GLP-1 receptor agonist, rather than administering it continuously. This creates a similar or enhanced variation in the plasma levels of GLP-1 receptor agonist as compared to the circadian variation of the endogenous GLP-1 receptor agonist in a healthy individual. A pharmaceutical composition for use in the dosage regimen containing GLP-1 receptor agonist as an active ingredient is also provided.

摘要翻译： GLP-1受体激动剂的新剂量方案几乎不引起副作用或药物相互作用，并且适用于改善胰岛素抵抗。 还提供了用于剂量方案中的胰岛素抵抗改善剂。 给药方案包括至少在进食预定时间段之前，优选以非侵入方式重复施用GLP-1受体激动剂，以产生与用餐后暂时分泌内源性GLP-1所观察到的相似的状况 受体激动剂，而不是连续给药。 与健康个体中内源性GLP-1受体激动剂的昼夜节律变化相比，这会在GLP-1受体激动剂的血浆水平上产生相似或增强的变化。 还提供了用于含有GLP-1受体激动剂作为活性成分的剂量方案中的药物组合物。